About: Characteristics of human infection with avian influenza viruses and development of new antiviral agents

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Characteristics of human infection with avian influenza viruses and development of new antiviral agents Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Characteristics of human infection with avian influenza viruses and development of new antiviral agents
Creator	Liu, Qiang Yang, Zhan-Qiu Liu, Dong-Ying
source	PMC
abstract	Since 1997, several epizootic avian influenza viruses (AIVs) have been transmitted to humans, causing diseases and even deaths. The recent emergence of severe human infections with AIV (H7N9) in China has raised concerns about efficient interpersonal viral transmission, polygenic traits in viral pathogenicity and the management of newly emerging strains. The symptoms associated with viral infection are different in various AI strains: H5N1 and newly emerged H7N9 induce severe pneumonia and related complications in patients, while some H7 and H9 subtypes cause only conjunctivitis or mild respiratory symptoms. The virulence and tissue tropism of viruses as well as the host responses contribute to the pathogenesis of human AIV infection. Several preventive and therapeutic approaches have been proposed to combat AIV infection, including antiviral drugs such as M2 inhibitors, neuraminidase inhibitors, RNA polymerase inhibitors, attachment inhibitors and signal-transduction inhibitors etc. In this article, we summarize the recent progress in researches on the epidemiology, clinical features, pathogenicity determinants, and available or potential antivirals of AIV.
has issue date	2013-10-07(xsd:dateTime)
bibo:doi	10.1038/aps.2013.121
bibo:pmid	24096642
has license	cc-by-nc-nd
sha1sum (hex)	cf899b3942af5e7e734cca1ce4f6ff1a1c82a9d9
schema:url	https://doi.org/10.1038/aps.2013.121
resource representing a document's title	Characteristics of human infection with avian influenza viruses and development of new antiviral agents
has PubMed Central identifier	PMC3791557
has PubMed identifier	24096642
schema:publication	Acta Pharmacol Sin
resource representing a document's body	covid:cf899b3942af5e7e734cca1ce4f6ff1a1c82a9d9#body_text
is schema:about of	named entity 'PROGRESS' named entity 'ARTICLE' named entity 'VIRAL TRANSMISSION' named entity 'INDUCE' named entity 'CONCERNS' named entity 'TRANSMITTED' named entity 'DETERMINANTS' named entity 'AVAILABLE' named entity 'DISEASES' named entity 'PREVENTIVE' named entity 'PATHOGENICITY' named entity 'VIRAL INFECTION' named entity 'RECENT' named entity 'PATHOGENESIS' named entity 'DEATHS' named entity 'RNA POLYMERASE INHIBITORS' named entity 'VIRULENCE' named entity 'H7N9' named entity 'AVIAN INFLUENZA' named entity 'EPIDEMIOLOGY' named entity 'RELATED' named entity 'H5N1' named entity 'responses' named entity 'combat' named entity 'pneumonia' named entity 'infection' named entity 'HUMAN' named entity 'INTERPERSONAL' named entity 'DEVELOPMENT' named entity 'H5N1' named entity 'MANAGEMENT' named entity 'AIV' named entity 'HUMANS' named entity 'INFLUENZA VIRUSES' named entity 'CAUSE' named entity 'SIGNAL-TRANSDUCTION' named entity 'ETC.' named entity 'SUBTYPES' named entity 'NEURAMINIDASE INHIBITORS' named entity '1997' named entity 'THERAPEUTIC' named entity 'COMBAT' named entity 'INHIBITORS' named entity 'CHINA' named entity 'TISSUE TROPISM' named entity 'ATTACHMENT' named entity 'RESPIRATORY SYMPTOMS' named entity 'EMERGENCE' named entity 'NEW' named entity 'CHARACTERISTICS' named entity 'STRAINS' named entity 'APPROACHES' named entity 'HUMAN' named entity 'VARIOUS' named entity 'EPIZOOTIC' named entity 'HAVE' named entity 'SEVERE PNEUMONIA' named entity 'COMPLICATIONS' named entity 'HOST' named entity 'AVIAN INFLUENZA' named entity 'INFECTION' named entity 'ANTIVIRAL AGENTS' named entity 'CLINICAL FEATURES' named entity 'PATIENTS' named entity 'MILD' named entity 'SYMPTOMS' named entity 'ANTIVIRALS' named entity 'VIRUSES' named entity 'ANTIVIRAL DRUGS' named entity 'INFLUENZA VIRUSES' named entity 'PROPOSED' named entity 'DIFFERENT' named entity 'NEWLY' named entity 'INFECTION' named entity 'ABOUT' named entity 'VIRAL' named entity 'CONJUNCTIVITIS' named entity 'RAISED' named entity 'POLYGENIC TRAITS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software